From:  Second- and third-line treatment agents in autoimmune hepatitis (AIH): Where do we stand?

 Characteristics of studies reporting treatment with MMF for naive, intolerant, or refractory AIH

AuthorYearTypePopulation (N)Follow up (months)PatientsResponse rates
Richardson et al. [36]2000Retrospective746271%
Devlin et al. [42]2004Retrospective5NA1100%
Czaja et al. [45]2005Retrospective81920%
Chatur et al. [37]2005Retrospective1126.5064%
Hlivko et al. [29]2007Retrospective2926284%
Inductivo-Yu et al. [44] 2007Retrospective1541273%
Hennes et al. [46]2008Retrospective36492Naive 43%
Refractory 25%
Sharzehi et al. [38]2010Retrospective2162Naive 88%
Refractory 0%
Zachou et al. [30]2011Prospective5926059%
Baven-Pronk et al. [39]2011Retrospective45372Naive 67%
Refractory 13%
Zachou et al. [31]2016Retrospective10967072%
Efe et al. [43]2017Retrospective121622Naive 92%
Refractory 34%
Nicoll et al. [27]2019Retrospective10532260%
Giannakopoulos et al. [41]2019Retrospective2271245%
Dalekos et al. [33]2022Prospective64450Naive 97%
Refractory 100%
Dalekos et al. [22]2022Retrospective18366096%
Kolev et al. [40]2022Retrospective50242Naive 82%
Refractory 30%
Return to article view

NA: not applicable; 0: naive/intolerance; 1: refractory; 2: both